



CLAYTON CHAU, MD, PhD  
DIRECTOR

STEVE THRONSON  
DEPUTY AGENCY DIRECTOR  
REGULATORY/MEDICAL SERVICES

TAMMI McCONNELL MSN, RN  
DIVISION DIRECTOR  
EMERGENCY MEDICAL SERVICES

405 W FIFTH STREET, SUITE 301A  
SANTA ANA, CALIFORNIA 92701  
TELEPHONE: 714- 834-2791  
FAX: 714- 834-3125  
Email: [TMcConnell@ochca.com](mailto:TMcConnell@ochca.com)

**MEDICAL HEALTH SERVICES**  
**EMERGENCY MEDICAL SERVICES**

Date: November 17, 2020  
To: Orange County Hospitals, Skilled Nursing Facilities, Urgent Cares/Clinics & Infusion Centers  
From: Dr. Carl Schultz, EMS Medical Director *CAS*  
**SUBJECT: BAMLANIVIMAB AVAILABLE FROM ORANGE COUNTY HEALTH CARE AGENCY**

The FDA has issued an Emergency Use Authorization (EUA) for the IV infusion of Bamlanivimab in outpatients diagnosed with COVID-19 at high risk for complications (attached).

**The Orange County Health Care Agency will be receiving allocations of this monoclonal antibody and is making it available to health care providers who request it by submitting a Resource Request to the Agency Operations Center (AOC).** The form can be found at: [HCA AOC Resource Request](#).

High risk is defined as patients who meet at least one of the following criteria:

- Have a body mass index (BMI) ≥35
- Have chronic kidney disease
- Have diabetes
- Have immunosuppressive disease
- Are currently receiving immunosuppressive treatment
- Are ≥65 years of age
- Are ≥55 years of age AND have
  - cardiovascular disease, OR
  - hypertension, OR
  - chronic obstructive pulmonary disease/other chronic respiratory disease.
- Are 12 – 17 years of age AND have
  - BMI ≥85th percentile for their age and gender based on CDC growth charts, [https://www.cdc.gov/growthcharts/clinical\\_charts.htm](https://www.cdc.gov/growthcharts/clinical_charts.htm), OR
  - sickle cell disease, OR
  - congenital or acquired heart disease, OR
  - neurodevelopmental disorders, for example, cerebral palsy, OR
  - a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR
  - asthma, reactive airway or other chronic respiratory disease that requires daily medication for control.

The drug is delivered intravenously over at least 1 hour and patient monitoring is necessary for at least an additional hour after drug administration is completed. Providers must have the capability to treat a severe infusion reaction, such as anaphylaxis (epinephrine, IV fluids, etc.), and the ability to activate the emergency medical system (EMS). Bamlanivimab is indicated for outpatients 12 years of age and older weighing at least 40 kg infected with SARS-CoV-2 not requiring supplemental oxygen within 10 days of symptom onset.